Brighton Jones LLC purchased a new stake in Evolent Health, Inc. (NYSE:EVH - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 349,109 shares of the technology company's stock, valued at approximately $3,927,000. Brighton Jones LLC owned approximately 0.30% of Evolent Health as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently made changes to their positions in EVH. Covestor Ltd boosted its position in shares of Evolent Health by 138.1% in the 3rd quarter. Covestor Ltd now owns 1,424 shares of the technology company's stock worth $40,000 after buying an additional 826 shares in the last quarter. GAMMA Investing LLC raised its position in Evolent Health by 5,365.5% during the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company's stock worth $45,000 after acquiring an additional 1,556 shares during the last quarter. Quarry LP purchased a new stake in shares of Evolent Health in the second quarter valued at about $32,000. Canada Pension Plan Investment Board acquired a new stake in shares of Evolent Health in the second quarter valued at approximately $61,000. Finally, Point72 Asia Singapore Pte. Ltd. increased its stake in shares of Evolent Health by 2,471.9% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 6,507 shares of the technology company's stock worth $184,000 after purchasing an additional 6,254 shares in the last quarter.
Analyst Upgrades and Downgrades
EVH has been the topic of a number of recent research reports. Canaccord Genuity Group reduced their target price on Evolent Health from $23.00 to $16.00 and set a "buy" rating on the stock in a research note on Thursday. Royal Bank of Canada reduced their price objective on Evolent Health from $20.00 to $17.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 14th. Stephens dropped their price objective on Evolent Health from $16.00 to $12.00 and set an "equal weight" rating for the company in a research report on Tuesday. Oppenheimer cut their target price on shares of Evolent Health from $28.00 to $18.00 and set an "outperform" rating for the company in a research note on Friday. Finally, Needham & Company LLC assumed coverage on shares of Evolent Health in a research note on Friday, January 10th. They set a "buy" rating and a $15.00 price target on the stock. One investment analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Evolent Health has a consensus rating of "Buy" and an average target price of $18.54.
Get Our Latest Research Report on Evolent Health
Evolent Health Trading Down 0.7 %
EVH stock traded down $0.08 during midday trading on Friday, reaching $10.11. 1,595,608 shares of the company's stock traded hands, compared to its average volume of 2,506,493. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04. Evolent Health, Inc. has a fifty-two week low of $9.74 and a fifty-two week high of $35.00. The business has a 50-day moving average price of $11.45 and a two-hundred day moving average price of $20.38. The company has a market capitalization of $1.18 billion, a P/E ratio of -11.10 and a beta of 1.45.
Evolent Health (NYSE:EVH - Get Free Report) last posted its earnings results on Thursday, November 7th. The technology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of $0.30 by ($0.38). Evolent Health had a negative net margin of 2.93% and a positive return on equity of 6.30%. The business had revenue of $621.40 million for the quarter, compared to analyst estimates of $625.58 million. During the same quarter in the previous year, the firm posted $0.19 EPS. Equities research analysts forecast that Evolent Health, Inc. will post 0.26 EPS for the current fiscal year.
Evolent Health Profile
(
Free Report)
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
Further Reading
Before you consider Evolent Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolent Health wasn't on the list.
While Evolent Health currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
